Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations.
about
Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysisThe Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Antidepressants, anxiolytics, and hypnotics in pregnancy and lactationSerotonin transporter variant drives preventable gastrointestinal abnormalities in development and function.Antidepressant use in pregnancy: a critical review focused on risks and controversiesPrenatal antidepressant exposure: clinical and preclinical findings.Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.Adverse drug reactions from psychotropic medicines in the paediatric population: analysis of reports to the Danish Medicines Agency over a decade.Perinatal outcomes of pregnancies complicated by maternal depression with or without selective serotonin reuptake inhibitor therapyExisting data sources for clinical epidemiology: Aarhus University Prescription DatabaseAntidepressant use in pregnancy and the risk of cardiac defectsSelective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects.National trends in antidepressant medication treatment among publicly insured pregnant womenAntidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records.Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study.Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence.Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy.Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysisMedical databases in studies of drug teratogenicity: methodological issuesLength of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.Treatment of nonpsychotic major depression during pregnancy: patient safety and challengesThe Nordic health registers - an important source when evaluating the safety of antidepressants during pregnancy.Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms.Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study.Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.The safety of antidepressant drugs during pregnancy.Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort studyEarly-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis.Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction.Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review.The effects of depression and use of antidepressive medicines during pregnancy on the methylation status of the IGF2 imprinted control regions in the offspring.Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort studyEffects of Fluoxetine on Human Embryo Development.Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort StudiesPrescribing antidepressants to pregnant women: what is a family physician to do?Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.Perinatal depression: treatment options and dilemmas.
P2860
Q21198704-07CDFFBD-B14E-4F03-9928-3D3CCC981ACDQ26741187-0201D029-DFBC-47E1-B912-A8BCA22F565EQ26795384-894CE824-B55A-4906-B693-51142222AC4FQ27329816-93BCB756-B7B4-4B99-A0ED-3644324ED5CEQ28281407-95B84C8A-F68D-4300-8738-70EEC50B7544Q30415540-EF4C54D6-1B94-4089-99A1-02EF2A48D1A2Q33521786-00F54DF1-6883-4202-9503-036E885A362BQ33614127-07D53DB6-744B-4B62-B4D4-7335A9334440Q33745085-749AB71D-2379-40DC-9BE2-D0D96AB2CE7DQ33770117-A73596B4-45F5-4140-8C80-93FC96E5DF72Q33775616-23725081-0784-497E-A0E4-199D153CE157Q33801507-AAF6CDDB-DC84-4FA8-BF18-D5CCAA000CFBQ33830556-6B44756F-88E6-47BF-8065-E84D57AFDCD3Q33841097-7CFDD496-7F54-49EF-A7DB-B75C6DD755F2Q34018881-580D5C8F-366B-4F3F-9478-6EC927EB04F8Q34047430-B4BF81EE-AFD5-4438-BD30-93D885708F2EQ34073546-F8062879-3358-4F12-9359-833EA65219D8Q34144128-DF5B39C3-4588-4E83-96EA-6431359606A2Q34144164-23EE8EC7-FB12-4713-8DD5-E931496587E9Q34178991-F921C8BB-8605-41FD-816D-2EBBECA29774Q34237681-6528AC8C-0141-41F3-9E24-C0F7E5ECB751Q34240630-1BCC756E-D154-4D35-8264-90AA5BA661ADQ34483257-ACB8EDD2-9A90-4882-988A-20448C88A416Q34516341-E3ABAEF9-A5FD-4F09-9662-1A6F738F58FBQ34590507-D59B86FB-2BA6-4098-BE29-1ED34D54B317Q34661348-3DA5D1DB-171D-4986-B363-0DC43A12976CQ34702282-71BCD35A-C043-4E56-A4B0-486C88A53729Q34714284-AD222520-62C4-4826-9DC3-9BFF72C41ADBQ35132422-2CCD77BB-9C38-459C-9EA8-A6B3BB2E136EQ35506589-6FE10731-7FC3-431B-87C2-371718F0CD75Q35541040-905A0CA9-9ECB-461B-B1EA-51E60FA4B685Q35608913-35B978CC-D807-4C99-9068-7A2278341DB8Q35640425-9A8BC79A-7459-4C5D-B5BE-4A27AB15EBC7Q35670663-501DF377-96F0-4827-A7BF-728D0EE1DB28Q36045075-E78D6DFA-DB13-4BE8-BD57-6D47A0DA3F01Q36068009-B38151F8-364B-433E-B77A-45C6E71128CCQ36141324-8DAAD120-09ED-4858-B06F-B70A5229B0FDQ36447517-3F80F298-8A52-4010-BC1C-68422490F207Q36536492-8A01EC3F-BD49-41D0-8AA3-30EDA6D219BFQ36737979-99407E28-D87B-4EC5-A27C-B38D82E45B2E
P2860
Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Maternal use of selective sero ...... k of congenital malformations.
@en
Maternal use of selective sero ...... k of congenital malformations.
@nl
type
label
Maternal use of selective sero ...... k of congenital malformations.
@en
Maternal use of selective sero ...... k of congenital malformations.
@nl
prefLabel
Maternal use of selective sero ...... k of congenital malformations.
@en
Maternal use of selective sero ...... k of congenital malformations.
@nl
P2093
P1433
P1476
Maternal use of selective sero ...... k of congenital malformations.
@en
P2093
Estrid Munk
Lars Pedersen
Loren Lipworth
Mette Gislum
Mette Nørgaard
Pia Wogelius
P304
P356
10.1097/01.EDE.0000239581.76793.AE
P577
2006-11-01T00:00:00Z